DUBLIN--(BUSINESS WIRE)--The "Preparing for FDA's New Import/Export Trauma in 2020" conference has been added to ResearchAndMarkets.com's offering.
The FDA continues to change its import program to better manage new problems and to use new procedures to make the whole process easier. The FDA and U.S. Customs and Border Protection (CBP) are relying more and more on computer programs to expedite the import process. When and how you use these programs can make a big difference in the net profit derived from even a single shipment. The new Voluntary Qualified Importer Program (VQIP) is one such example. Another example is CBP's and FDA's implementation of the Automated Commercial Environment (ACE) program became mandatory for importers in 2016. If you fail to correctly use new import procedures and programs, you will be operating under an expensive disadvantage.
- FDA's new cost-saving import programs
- Understand how U.S. Customs and FDA legal requirements intersect
- Know how to manage foreign suppliers
- Understand the FDA's internal procedures
- Learn how to mitigate and resolve import detentions
- Learn how to avoid common problems
- Develop practical ways to improve your import and export business
You will be able to answer the following questions with this course without saying, I don't know?
- What are the FDA's import legal requirements and policies?
- How do you deal with the FDA and the U.S. Customs and Border Patrol procedures?
- What happens when your product is detained?
- What happens if a foreign manufacturer is in trouble with the FDA?
- How do you interact with the FDA to work out problems?
- Why are import and export rules different or does it even matter?
FDA's import and export program is complex and keeps changing. The FDA's and the U.S. Custom's new import and enforcement program operates with a streamlined computer system and can leave firms at a loss to understand the short term and long term effects of a detained shipment. The law now requires foreign firms to register and submit specific information to enter U.S. commerce.
Foreign establishments are subject to FDA inspections and quality testing. Failing either FDA activity typically prevents a foreign firm's product from entering U.S. commerce. If a product is detained, resolving the problem with the FDA is time-consuming, expensive and uncertain. Without an adequate or informed approach to your import program, the specialized federal government process and roadblocks can seem impossible to overcome. To compound the problems, working with foreign establishments presents inherent difficulties based on cultural differences business practices and language barriers.
Other foreign and domestic and legal requirements intersect with FDA's import and export program, some for the better, some not. For example, not all foreign firms are treated the same under the FDA's law. A clear example is the FDA's uses of automatic detention based on the country of origin, type of product or an establishment's history. With the growing use of off-shore operations, managing imported products can and does present obvious and hidden
Seminar Fee Includes:
- AM-PM Tea/Coffee
- Seminar Material
- USB with seminar presentation
- Hard copy of the presentation
- Attendance Certificate
- $100 Gift Cert for the next seminar
Day 01 (8:30 AM - 4:30 PM)
08.30 AM - 09.00 AM: Registration
09.00 AM: Session Start
Day 1 - Morning
FDA's legal requirements
- Statutory authority
Foreign manufacturers obligations
- U.S. initial importers obligations
- User Fees
- How does FDA do its job
- What is CPB and how do they do their job
Selecting foreign suppliers
- Inspection history
- Samples analyzed
- Vendor Audit
Day 1 - Afternoon
Product Import Procedures
- Entry Process (U.S. Customs/FDA)
- How to Pick the right Custom House Broker
Day 02 (8:30 AM - 4:00 PM)
Day 2 - Morning
Foreign Inspections by the FDA and EU Notified Bodies
- Options for a detained shipment
- Negotiating with FDA and U.S. Customs
- Release from Detention and Government Refusal Remedies
- Reducing the risk of detention
(Group study for mitigating detention risks)
Day 2 - Afternoon
FDA Warning Letters and Automatic Detention
- U.S. Customs and FDA authority
- Burden of proof
- Assistant U.S. attorney
- Government remedies
- Import for export
- International trade shows
- Investigational device
- Compassionate Use
New and Special Issues for Imports and Exports in 2020.
- EU Medical Device Regulation (MDR) program for imported products
- Inspection of personal mail
- Personal use exception
- Trade shows and promotional marketing
- Compassionate use.
Casper (Cap) Uldriks
Former Associate Center Director
Through his firm Encore Insight LLC, Casper brings over 32 years of experience from the FDA. He specialized in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. His comments are candid, straightforward and of practical value. He understands how FDA thinks, how it operates and where it is headed. Based on his exceptionally broad experience and knowledge, he can synthesize FDA's domestic and international operational programs, institutional policy and thicket of legal variables into a coherent picture.
For more information about this conference visit https://www.researchandmarkets.com/r/gc80zs